Bivigam FDA Approval History
FDA Approved: Yes (First approved December 21, 2012)
Brand name: Bivigam
Generic name: immune globulin intravenous
Dosage form: Infusion
Company: Biotest Pharmaceuticals Corporation
Treatment for: Primary Immunodeficiency Syndrome
Bivigam is an immune globulin intravenous (human) indicated for the treatment of primary humoral immunodeficiency.
Development Timeline for Bivigam
|May 10, 2019||ADMA Announces It Will Reintroduce Bivigam Into the Market|
|Dec 21, 2012||FDA Approves Biotest's Bivigam, an Intravenous Immune Globulin (Human), 10% Liquid|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.